(Q33343275)

English

The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

Reginald F. Munden

object named as

Reginald F Munden

17

0 references

1

object named as

Roy S Herbst

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Vassiliki Papadimitrakopoulou

9

object named as

Vassiliki A Papadimitrakopoulou

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

George R Blumenschein

11

object named as

George Blumenschein

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Frank V Fossella

5

object named as

Frank V Fossella

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

18

object named as

Waun Ki Hong

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Fadlo R Khuri

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Charles Lu

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Diane D Liu

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Bonnie S Glisson

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Katherine M W Pisters

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dong M Shin

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jonathan M Kurie

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Merrill S Kies

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ralph Zinner

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Maria S Jung

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Robert Lu

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J Jack Lee

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jin Soo Lee

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 July 2002

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

95

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

340-353

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin Investigators

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Gemcitabine plus vinorelbine for the treatment of advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma: a phase II multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

21 January 2018

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

7 January 2021

based on heuristic

inferred from DOI database lookup

ZD1839 (Iressa) in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10629

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.10629

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33343275&oldid=1844113585"